
CLAIMS

1. The compound BP1.4979, of formula:



,

N-(4-{2-[4-(3-Cyanophenyl)piperazin-1-yl]ethyl}cyclohexyl)-3-methoxypropanamide or a pharmaceutically acceptable salt thereof, or its hydrates, or hydrated salts, or the polymorphic, crystalline structures thereof,

for use for treating or preventing a disorder of the central nervous system (CNS).

2. Compound BP1.4979 for use according to claim 1 wherein said disorder is selected from the restless leg syndrome (RLS), essential tremor, binge eating disorder, and neurodegenerative diseases.

3. Compound BP1.4979 for use according to anyone of the preceding claims wherein said disorder is RLS.

4. Compound BP1.4979 for use according to anyone of the preceding claims wherein said disorder is neurodegenerative disease.

5. Compound BP1.4979 for use according to anyone of claims 2 to 4, wherein said neurodegenerative disease is selected from Parkinson's disease (PD), Alzheimer's disease (AD) and Huntington's disease (HD).

6. Compound BP1.4979 for use according to anyone of claims 1 to 2, wherein said disorder is essential tremor.

7. Compound BP1.4979 for use according to anyone of claims 1 to 2, wherein said disorder is binge eating disorder.